About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

SUSPENDEDPhase 2

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients

NCT00986284•Tianjin Medical University Cancer Institute and Hospital

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Non Small Cell Lung Cancer

Interventions

gefitinib

Locations

1

China

Locations (1)

Tianjin Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

Key Dates

Start Date

September 1, 2009

Primary Completion Date

November 1, 2016

Completion Date

November 1, 2016

Last Updated

December 22, 2015

Related Studies

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

RECRUITINGPhase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

RECRUITINGPhase 1/2

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132

Advanced Solid TumorNon Small Cell Lung Cancer+2 more

RECRUITINGPhase 3

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

NCT06284317

Non Small Cell Lung Cancer

RECRUITINGPhase 2

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

NCT06731413

Non-Small Cell Lung CancerNSCLC+2 more

RECRUITINGPhase 3

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

NCT06687369

Non Squamous Non Small Cell Lung Cancer

View all related studies

Sponsors

Lead Sponsor

Tianjin Medical University Cancer Institute and Hospital

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 22, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions